PARP3 comes to light as a prime target in cancer therapy Rodríguez-Vargas, José Manuel Nguekeu-Zebaze, Léonel Dantzer, Francoise Poly (ADP-ribose) polymerase 3 mTORC2 cancer aggressiveness This work was supported by Association pour la Recherche contre le Cancer, Ligue Nationale Contre le Cancer, CNRS, Université de Strasbourg and Ramon Areces Foundation. This work has been published within the LABEX ANR-10-LABX-0034_Medalis. Poly(ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family that catalyze a post-translational modification of proteins to promote, control or adjust numerous cellular events including genome integrity, transcription, differentiation, cell metabolism or cell death. In the late years, PARP3 has been specified for its primary functions in programmed and stressinduced double-strand break repair, chromosomal rearrangements, transcriptional regulation in the zebrafish and mitotic segregation. Still, deciphering the therapeutic value of its inhibition awaits additional investigations. In this review, we discuss the newest advancements on the specific functions of PARP3 in cancer aggressiveness exemplifying the relevance of its selective inhibition for cancer therapy. 2026-02-10T13:45:49Z 2026-02-10T13:45:49Z 2019-06-18 journal article Rodriguez-Vargas, J. M., Nguekeu-Zebaze, L., & Dantzer, F. (2019). PARP3 comes to light as a prime target in cancer therapy. Cell Cycle, 18(12), 1295–1301. https://doi.org/10.1080/15384101.2019.1617454 https://hdl.handle.net/10481/110837 10.1080/15384101.2019.1617454 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ open access Attribution-NonCommercial-NoDerivatives 4.0 Internacional Taylor & Francis